The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech’s litifilimab.

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Researchers at Linköping University in Sweden made an unexpected discovery while investigating genetically unique women.

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Why does Seal have scars? The singer's facial scars and bumps are caused by a skin condition. Learn what happened to his face ...

Columnist Candace Semien applies the concept of radical responsibility to managing lupus and other chronic health conditions.